Search Results

Imagine running a calcium assay and discovering your compound shows only weak activity. Kenakin dives deep into a widely used, often misunderstood tool in early drug discovery: the calcium assay Revered for its convenience, the FLIPR assay provides rapid insights into receptor activity. with strategic clarity. 📍 Foundational Level | Calcium Assays 📚 Part of Terry Kenakin’s Pharmacology Unlock "Calcium Assays" now

Thus we propose the use of fluorescent probes in GPCR screening assays due to their numerous advantages The advantages of Fluorescent Probes in GPCR assays over other methods Fluorescent ligands are made by The traditional binding assays for GPCRs use radioligands, whose limitations, especially safety concerns At Celtarys, we focus on developing fluorescent tools that keep minimal background signal even without common starting point for employing fluorescent probes in GPCR assays.

Radioligands have been used to study GPCRs for decades, but with the advances in the fluorescence field, assays They are ligands labeled with radioactive isotopes which can be used in binding assays to quantify other that offer an alternative to radioligands in binding assays. design for specific targets:  Not all targets have available high-affinity radioligands, but with the development GPCR-radioligand binding assays.

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this probes for GPCR assays. GPCR, Celtarys will bring those lessons to the broader community, providing insight into assay development Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, , GPCR assay development , G protein-coupled receptors , GPCR podcast , Celtarys partnership Summary

David has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development role and most recently with Novartis. His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

His current work is mainly focused on screening and assay development to bridge the gap between in vitro